HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2015. Quarter ended June 30, 2015 Highlights - compared to June 30, 2014 Net sales of $215 million, reflects an increase of $85 million. Last year’s quarter net sales were negatively impacted by a $79 million provision for price protection (current quarter’s price protection provision was $14 million). On a pro-form
| < Prev | Next > |
|---|
